newsfilter
← Latest News
Business Wire·

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of